- Home
- OB vs CLYM Comparison
OB vs CLYM Comparison
Compare OB & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OB
- CLYM
- Stock Information
- Founded
- OB 2006
- CLYM 2018
- Country
- OB United States
- CLYM United States
- Employees
- OB N/A
- CLYM N/A
- Industry
- OB Industrial Machinery/Components
- CLYM
- Sector
- OB Industrials
- CLYM
- Exchange
- OB Nasdaq
- CLYM NYSE
- Market Cap
- OB 219.5M
- CLYM 242.8M
- IPO Year
- OB 2021
- CLYM 2021
- Fundamental
- Price
- OB $5.10
- CLYM $3.00
- Analyst Decision
- OB Buy
- CLYM
- Analyst Count
- OB 5
- CLYM 0
- Target Price
- OB $5.50
- CLYM N/A
- AVG Volume (30 Days)
- OB 116.7K
- CLYM 317.4K
- Earning Date
- OB 11-07-2024
- CLYM 11-12-2024
- Dividend Yield
- OB N/A
- CLYM N/A
- EPS Growth
- OB N/A
- CLYM N/A
- EPS
- OB N/A
- CLYM N/A
- Revenue
- OB $903,518,000.00
- CLYM N/A
- Revenue This Year
- OB $1.24
- CLYM N/A
- Revenue Next Year
- OB $7.66
- CLYM N/A
- P/E Ratio
- OB N/A
- CLYM N/A
- Revenue Growth
- OB N/A
- CLYM N/A
- 52 Week Low
- OB $3.42
- CLYM $2.35
- 52 Week High
- OB $5.48
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- OB 60.54
- CLYM N/A
- Support Level
- OB $4.91
- CLYM N/A
- Resistance Level
- OB $5.48
- CLYM N/A
- Average True Range (ATR)
- OB 0.20
- CLYM 0.00
- MACD
- OB 0.03
- CLYM 0.00
- Stochastic Oscillator
- OB 69.60
- CLYM 0.00
About OB Outbrain Inc.
Outbrain Inc is a platform powering the open web that matches audiences with personalized content and ads, driving quality engagement. Its platform delivers ads to end-users that appear as links to articles, products, and videos on media partners' sites. It derives revenue from advertisers through user engagement with the ads that it places on media partners' web pages and mobile applications. The company has its geographic presence in Europe, the Middle East, and Africa followed by the USA and others.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.